Nathan Carlson1, Robert Mah2, Maria Aburto3, Mark Jason Peters4, Meagan V Dupper5, Lie Hong Chen6. 1. Family Physician and Faculty of the Family Medicine Residency Program at the Fontana Medical Center in CA. nathan.d.carlson@kp.org Biostatistician in Research and Evaluation for the Southern California Permanente Medical Group in Pasadena, CA. lie.h.chen@kp.org. 2. Family Medicine Resident at the Fontana Medical Center in CA. robert.x.mah@kp.org Biostatistician in Research and Evaluation for the Southern California Permanente Medical Group in Pasadena, CA. lie.h.chen@kp.org. 3. Research Assistant at the Fontana Medical Center in CA. maria.x.aburto@kp.org Biostatistician in Research and Evaluation for the Southern California Permanente Medical Group in Pasadena, CA. lie.h.chen@kp.org. 4. Family Medicine Physician at the Oceanside Medical Offices in CA. jason.m.peters@kp.org Biostatistician in Research and Evaluation for the Southern California Permanente Medical Group in Pasadena, CA. lie.h.chen@kp.org. 5. Community Medicine Fellow at the Fontana Medical Center in CA. meagan.v.dupper@kp.org Biostatistician in Research and Evaluation for the Southern California Permanente Medical Group in Pasadena, CA. lie.h.chen@kp.org. 6. Biostatistician in Research and Evaluation for the Southern California Permanente Medical Group in Pasadena, CA. lie.h.chen@kp.org.
Abstract
CONTEXT: Hypovitaminosis D has been implicated as a possible risk factor for the development of cardiovascular disease. High-sensitivity C-reactive protein (hs-CRP) has been one of the most extensively studied biomarkers for cardiovascular inflammation as an indicator of disease and event risk, independent of traditional risk factors. To date, it is unclear if correction of hypovitaminosis D leads to a reduction of hs-CRP in human subjects. OBJECTIVES: To assess laboratory validity of 25-hydroxyvita-min D (25-OH-vitamin D) and hs-CRP measurements and to determine whether hs-CRP levels in adults with well-controlled hypertension and comorbid low vitamin D levels changed after hypovitaminosis D correction to a serum 25-OH-vitamin D level greater than 30 ng/mL. DESIGN: Prospective study using an unblinded design. RESULTS: One hundred eight subjects who were vitamin D insufficient or deficient completed this study. The mean 25-OH-vitamin D level was 20.07 ng/mL before treatment and 43.92 ng/mL after treatment. Posttreatment vitamin D levels were in the normal range for 91% of the subjects. No statistically significant changes in hs-CRP level were detected after the vitamin D treatment was administered and a posttreatment vitamin D level above 30 ng/mL was confirmed. CONCLUSION: We did not detect a statistically significant difference in hs-CRP after correction of hypovitaminosis D. Twelve weekly oral doses of 50,000 IU of ergocalciferol corrected the hypovitaminosis D in more than 90% of cases.
CONTEXT: Hypovitaminosis D has been implicated as a possible risk factor for the development of cardiovascular disease. High-sensitivity C-reactive protein (hs-CRP) has been one of the most extensively studied biomarkers for cardiovascular inflammation as an indicator of disease and event risk, independent of traditional risk factors. To date, it is unclear if correction of hypovitaminosis D leads to a reduction of hs-CRP in human subjects. OBJECTIVES: To assess laboratory validity of 25-hydroxyvita-min D (25-OH-vitamin D) and hs-CRP measurements and to determine whether hs-CRP levels in adults with well-controlled hypertension and comorbid low vitamin D levels changed after hypovitaminosis D correction to a serum 25-OH-vitamin D level greater than 30 ng/mL. DESIGN: Prospective study using an unblinded design. RESULTS: One hundred eight subjects who were vitamin Dinsufficient or deficient completed this study. The mean 25-OH-vitamin D level was 20.07 ng/mL before treatment and 43.92 ng/mL after treatment. Posttreatment vitamin D levels were in the normal range for 91% of the subjects. No statistically significant changes in hs-CRP level were detected after the vitamin D treatment was administered and a posttreatment vitamin D level above 30 ng/mL was confirmed. CONCLUSION: We did not detect a statistically significant difference in hs-CRP after correction of hypovitaminosis D. Twelve weekly oral doses of 50,000 IU of ergocalciferol corrected the hypovitaminosis D in more than 90% of cases.
Authors: John G Canto; Catarina I Kiefe; William J Rogers; Eric D Peterson; Paul D Frederick; William J French; C Michael Gibson; Charles V Pollack; Joseph P Ornato; Robert J Zalenski; Jan Penney; Alan J Tiefenbrunn; Philip Greenland Journal: JAMA Date: 2011-11-16 Impact factor: 56.272
Authors: Harald Dobnig; Stefan Pilz; Hubert Scharnagl; Wilfried Renner; Ursula Seelhorst; Britta Wellnitz; Jürgen Kinkeldei; Bernhard O Boehm; Gisela Weihrauch; Winfried Maerz Journal: Arch Intern Med Date: 2008-06-23
Authors: Thomas J Wang; Michael J Pencina; Sarah L Booth; Paul F Jacques; Erik Ingelsson; Katherine Lanier; Emelia J Benjamin; Ralph B D'Agostino; Myles Wolf; Ramachandran S Vasan Journal: Circulation Date: 2008-01-07 Impact factor: 29.690
Authors: Pieter H Myburgh; G Wayne Towers; Iolanthé M Kruger; Cornelie Nienaber-Rousseau Journal: Int J Environ Res Public Health Date: 2018-01-10 Impact factor: 3.390
Authors: Petro H Rautenbach; Cornelie Nienaber-Rousseau; Zelda de Lange-Loots; Iolanthé M Kruger; Marlien Pieters Journal: Front Cardiovasc Med Date: 2022-07-12
Authors: Helen F Titmarsh; Adam G Gow; Scott Kilpatrick; Jennifer A Cartwright; Elspeth M Milne; Adrian W Philbey; Jacqueline Berry; Ian Handel; Richard J Mellanby Journal: PLoS One Date: 2015-09-02 Impact factor: 3.240
Authors: Nonanzit Pérez-Hernández; Gad Aptilon-Duque; María Cristina Nostroza-Hernández; Gilberto Vargas-Alarcón; José Manuel Rodríguez-Pérez; Ruben Blachman-Braun Journal: Korean J Intern Med Date: 2016-04-27 Impact factor: 2.884